Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ClearPoint Neuro, Inc. (CLPT)

ClearPoint Neuro stockholders approve 2013 incentive plan, elect seven directors

Neutral Impact 3 of 5 shareholder Written later

At its annual meeting on May 20, 2026, ClearPoint Neuro stockholders approved the Seventh Amended and Restated 2013 Incentive Compensation Plan, elected seven directors to serve until the 2027 annual meeting, and ratified Cherry Bekaert LLP as auditor for 2026. The Board also confirmed R. John Fletcher as Chairman and set new committee memberships, so shareholders now have the plan's terms and an updated board structure in place.

Key points

  • Incentive plan approved with 7,517,634 votes for, 1,793,261 against and 495,788 abstentions.
  • All seven director nominees elected; Joseph M. Burnett received 9,686,224 votes for and 120,459 withheld.
  • Advisory vote on executive compensation: 8,825,126 for, 442,728 against and 538,829 abstentions.
  • R. John Fletcher confirmed as Board Chairman; Lynnette C. Fallon chairs the Audit Committee and B. Kristine Johnson chairs the Compensation Committee.

The filing

CompanyClearPoint Neuro, Inc. (CLPT)
Form8-K, current report
Filed with the SECMay 21, 2026, 4:30 PM ET
Accession number0001193125-26-234571

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.